Immunotherapy May Increase the Risk of Treatment Discontinuation in SCLC
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
The risk of hyperprogression is lower when atezolizumab is given upfront to patients with advanced non-small cell lung cancer, a study suggests.
A phase 2 trial suggests that frontline osimertinib and platinum-based chemotherapy is safe and effective in EGFR-mutated, advanced NSCLC.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
COVID-19 vaccination may reduce the risk of COVID-19 sequelae in patients with cancer, according to researchers.
Artificial intelligence can predict survival in cancer patients using information from a patient’s initial consultation with an oncologist, a study suggests.
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
Cancer patients living in nursing homes are more likely to receive aggressive end-of-life care and die in the hospital, a study suggests.
Five-year data support the use of pembrolizumab plus pemetrexed-platinum chemotherapy as standard care for previously untreated, metastatic, EGFR/ALK-wild-type NSCLC, according to researchers.
Patients with cancer experienced symptoms of PTSD during the first year of the COVID-19 pandemic, a French study suggests.